1. Home
  2. MESO vs TCBK Comparison

MESO vs TCBK Comparison

Compare MESO & TCBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • TCBK
  • Stock Information
  • Founded
  • MESO 2004
  • TCBK 1975
  • Country
  • MESO Australia
  • TCBK United States
  • Employees
  • MESO N/A
  • TCBK N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • TCBK Major Banks
  • Sector
  • MESO Health Care
  • TCBK Finance
  • Exchange
  • MESO Nasdaq
  • TCBK Nasdaq
  • Market Cap
  • MESO 1.3B
  • TCBK 1.4B
  • IPO Year
  • MESO N/A
  • TCBK N/A
  • Fundamental
  • Price
  • MESO $11.06
  • TCBK $42.68
  • Analyst Decision
  • MESO Buy
  • TCBK Buy
  • Analyst Count
  • MESO 4
  • TCBK 6
  • Target Price
  • MESO $18.00
  • TCBK $47.80
  • AVG Volume (30 Days)
  • MESO 205.5K
  • TCBK 110.1K
  • Earning Date
  • MESO 08-28-2025
  • TCBK 07-24-2025
  • Dividend Yield
  • MESO N/A
  • TCBK 3.10%
  • EPS Growth
  • MESO N/A
  • TCBK 4.60
  • EPS
  • MESO N/A
  • TCBK 3.43
  • Revenue
  • MESO $5,670,000.00
  • TCBK $389,795,000.00
  • Revenue This Year
  • MESO $178.09
  • TCBK $7.08
  • Revenue Next Year
  • MESO $305.06
  • TCBK $5.38
  • P/E Ratio
  • MESO N/A
  • TCBK $12.40
  • Revenue Growth
  • MESO N/A
  • TCBK 1.12
  • 52 Week Low
  • MESO $5.78
  • TCBK $35.20
  • 52 Week High
  • MESO $22.00
  • TCBK $51.06
  • Technical
  • Relative Strength Index (RSI)
  • MESO 50.02
  • TCBK 61.76
  • Support Level
  • MESO $10.32
  • TCBK $40.34
  • Resistance Level
  • MESO $10.86
  • TCBK $43.25
  • Average True Range (ATR)
  • MESO 0.35
  • TCBK 1.10
  • MACD
  • MESO 0.00
  • TCBK 0.21
  • Stochastic Oscillator
  • MESO 45.04
  • TCBK 89.22

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

Share on Social Networks: